2023
DOI: 10.1016/j.hrcr.2023.03.016
|View full text |Cite
|
Sign up to set email alerts
|

Pulsed field ablation using a focal contact force catheter allowed successful ablation of a focal right atrial tachycardia in the proximity of the phrenic nerve

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 8 publications
(3 citation statements)
references
References 12 publications
0
3
0
Order By: Relevance
“…As mentioned, we also successfully ablated one focal atrial tachycardia from the terminal crest in the right atrium as part of PVI ( +). Recently, a case report highlighted the possibilities of successful FPFA of an AT in close proximity to the phrenic nerve [ 25 ].…”
Section: Discussionmentioning
confidence: 99%
“…As mentioned, we also successfully ablated one focal atrial tachycardia from the terminal crest in the right atrium as part of PVI ( +). Recently, a case report highlighted the possibilities of successful FPFA of an AT in close proximity to the phrenic nerve [ 25 ].…”
Section: Discussionmentioning
confidence: 99%
“…All these data are derived from patients undergoing PVI with single-shot PFA devices. Despite 1 case report describing successful and safe endocardial PFA energy delivery directly at the site of maximal phrenic nerve capture, 14 safety data remain poor in this situation. In our patient, phrenic stimulation at the end of the procedure still demonstrated phrenic capture (manual diaphragmatic palpation and diaphragmatic excursion on fluoroscopy) without any signs of phrenic nerve injury during follow-up.…”
Section: Discussionmentioning
confidence: 99%
“…Due to their well-established risk profiles and broad market penetration, thermal cardiac ablation techniques are the tools of choice for invasive cardiologists and cardiac surgeons aiming to modify atrial arrhythmogenic substrate. PFA has slowly gained enthusiasm, though not approved by the Food and Drug Administration at this time, and is being evaluated for its efficacy in decreasing arrhythmogenic burden in supraventricular tachycardia [34] , atrial tachycardia [35,36] , atrial flutter [37] , and atrial fibrillation [38] . In the nonpharmacologic management of atrial fibrillation, the plasticity of atrial substrate may necessitate multiple ablation procedures, including repeat pulmonary vein isolations or lesion extension to deal with postablation macroreentrant atrial tachycardia.…”
Section: Efficacy and Pulmonary Vein Stenosismentioning
confidence: 99%